Athos Capital’s ResMed RMD Stock Holding History

Athos Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,544	Closed	-$1.18M	–	151
2020 Q4	$1.18M	Buy	5,544 +1,315	+31%	+$262K	0.32%	48
2020 Q3	$725K	Buy	+4,229	New	+$781K	0.35%	47
2018 Q1	–	Sell	-24,922	Closed	-$2.11M	–	29
2017 Q4	$2.11M	Buy	24,922 +22,122	+790%	+$1.83M	2.04%	14
2017 Q3	$215K	Sell	2,800 -5,889	-68%	-$450K	0.16%	33
2017 Q2	$677K	Buy	+8,689	New	+$622K	0.39%	26

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Athos Capital's RMD Position: Q1 2021 in Review

Athos Capital sold out of ResMed (RMD) in Q1 2021, closing a stake of 5,544 shares — an estimated $1.18M sold.

Athos Capital first reported a position in RMD in Q2 2017 and held it in 5 quarters. The position peaked at $2.11M in Q4 2017. 663 funds tracked by Wall St. Rank hold RMD as of Q1 2021.

Athos Capital reported no remaining ResMed position as of Q1 2021 after selling out during the quarter.
Athos Capital sold 5,544 ResMed shares in Q1 2021, an estimated $1.18M.
Athos Capital first reported a position in ResMed in Q2 2017 and held it in 5 quarters.
Athos Capital's ResMed position peaked at $2.11M in Q4 2017.
663 funds tracked by Wall St. Rank held ResMed as of Q1 2021.

Based on Athos Capital's 13F filing for Q1 2021, filed 14 May 2021.